Pfizer ED claim is sound, ASA rules

Acomplaint challenging a claim made by Pfizer in an advertisement for its Viagra Connect erectile dysfunction (ED) drug that “4.3 million men in the UK experience erectile problems” has not been upheld by the UK Advertising Standards Authority (ASA).

Acomplaint challenging a claim made by Pfizer in an advertisement for its Viagra Connect erectile dysfunction (ED) drug that “4.3 million men in the UK experience erectile problems” has not been upheld by the UK Advertising Standards Authority (ASA).

The ASA concluded that the national advertising campaign – which appeared on major UK television channels throughout the summer (OTC bulletin, 22 June 2018, page 16) – “made clear” that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Business

Reckitt Leans On Intimate Wellness Brands As OTC Stumbles

 
• By 

Gains for its Intimate Wellness portfolio - including a strong showing from Durex - helped offset lower sales of Reckitt's OTC cold & flu remedies in Q1. CEO Kris Licht shared his thoughts on the impact of US tariffs on the business and planned future divestments.

US Consumer Health Market People News: CHPA Foundation Contest, Celsius And AdvoCare Hires

 

CHPA Health In Hand Foundation accepting nominations for 2025 US Self-Care Marketing Awards; Celsius hires former PepsiCo as president/COO and closes $1.8bn acquisition of energy drink competitor Alani; and AdvoCare adds John Peirano as integrated marketing VP after hiring Kathy Blosser supply chain VP.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”